R&D News | pharmaphorum

News

Janssen J&J Johnson and Johnson pharmaceutical companies

New data sets up potential new gastro use for J&J's Stelara

Janssen’s Stelara has shown positive results in an ulcerative colitis (UC) trial, setting up a potential new indication for the inflammatory diseases drug.

News

Novartis drug cuts serious complications in sickle cell dise...

Novartis’ developmental sickle cell disease drug crizanlizumab cut occurrences of a serious complication of the disease that can lead to irreversible or fatal organ damage, according to mid

News

DNA helix in a futuristic concept of the evolution of science and medicine.

UK biotech Orchard plans $172.5m US IPO to fund rare disease...

UK biotech Orchard Therapeutics is planning a US IPO to expand use of its Strimvelis gene therapy, and further develop its rare disease pipeline.

News

Novartis chases untapped MS market with siponimod

US and European regulators have accepted filings for Novartis’s siponimod for secondary progressive multiple sclerosis (SPMS).

News

Lilly unveils promising data from dual-action diabetes drug

Eli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial results announced this week.

News

Trial shows Roche's new flu drug helps reduce symptoms in at...

Baloxavir marboxil, a flu drug seen by Roche as a successor to Tamiflu, significantly sped time to relief for patients highly vulnerable to serious complications.

New data sets up potential new gastro use for J&J's Stelara

Novartis drug cuts serious complications in sickle cell dise...

UK biotech Orchard plans $172.5m US IPO to fund rare disease...

Novartis chases untapped MS market with siponimod

Lilly unveils promising data from dual-action diabetes drug

Trial shows Roche's new flu drug helps reduce symptoms in at...

Clock starts ticking on UK's single patient record plan

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks